行情

PTGX

PTGX

Protagonist
NASDAQ

实时行情|Nasdaq Last Sale

13.88
+0.10
+0.73%
交易中 10:42 09/20 EDT
开盘
13.79
昨收
13.78
最高
13.91
最低
13.71
成交量
3.62万
成交额
--
52周最高
16.67
52周最低
5.49
市值
3.65亿
市盈率(TTM)
-5.1078
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PTGX 新闻

  • 在央行与市场的拉锯中 中性立场成为了新鹰派
  • 新浪财经综合.3小时前
  • 美联储官员Bullard:加大降息幅度将确保防止通胀放缓
  • 新浪财经综合.3小时前
  • 又一流氓交易员因做多原油及衍生品损失3.2亿美元
  • 新浪财经-自媒体综合.5小时前
  • 谷歌宣布对可再生能源进行重大投资
  • 新浪财经综合.5小时前

更多

所属板块

生物技术和医学研究
+0.79%
制药与医学研究
+1.19%

热门股票

名称
价格
涨跌幅

PTGX 简况

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
展开

Webull提供Protagonist Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。